(b).
| Anti-CD20 | ||||
| Rituximab | Phase 2 | Chemo, vorinostat, | ||
| Phase 3 | bortezomib | |||
| Ofatumumab | Phase 1 | |||
| Ublituximab 90Y/131I | + lenalidomide | |||
| maintenance | ||||
| + ASCT | ||||
| 51 studies | ||||
| Anti-CD56 131I | ||||
| 3 studies | Phase 1 | + ASCT | ||
| Anti-VEGF | ||||
| Monoclonal antibodies 158 studies |
bevacizumab | Phase 2 | 3 studies | |
| Anti-VEGF kinase | ||||
| (cediranib) | Phase 1 | + bevacizumab | ||
| Anti-transferrin R | Phase 1 | |||
| Anti-CTLA4 | Phase 1/2 | 4 studies | ||
| Anti-HLA DR | 2 studies | Phase 1 | ||
| Anti-CD22 | Phase 1 | 1 study | ||
| Anti-CD22 90Y | Phase 1/2 | + anti-CEA In111 1 study | ||
| Mantle cell lymphoma 860 studies |
Anti-CD22 In111 | Phase 1/2 | ||
| Anti-α-v β3 integrin | Phase 1 | |||
| Anti-CD19 | Phase 1/2 | |||
| Anti-CD74 | Phase 1/2 | + veltuzumab (humanized MoAb) | ||
| Anti-IGF-1R | Phase 1/2 | |||
| ganitumab | ||||
| Anti-TRAIL R2 | Phase 1 | + bortezomib/vorinostat | ||
| conatumumab | ||||
| Anti-PI3K | Idelalisib | Phase 1 | Chemo/rituximab | |
| BKM120 | Phase 1 | + rituximab | ||
| Anti-BTK | Ibrutinib | Phase 1 | Chemo/rituximab | |
| Anti-cdk | Flavopiridol | Phase 1 | + chemo/rituximab | |
| mTOR inhibitor | Temsirolimus | Phase 2 | + rituximab | |
| Phase 1/2 | + cladribine/rituximab | |||
| Anti-endosialin/TEM1 | Phase 1 | |||
| HDAC | Romidepsin | Phase 1/2 | + rituximab/lenalidomide | |
| Anti-bcl2 | Oblimersen | Phase 2 | + rituximab | |
| Obatoclax | + chemo/rituximab | |||
| Aurora-kinase inhibitor | Alisertib | Phase 2 | +/− rituximab | |
| Dehydrogenase inhibitor | CPI-613 | Phase 1 | + bendamustine/rituximab | |
| HDAC | Vorinostat | Phase 1/2 | + chemo | |
| Toll-R agonists | CPG 7909 | Phase 2 | + chemo |